MALE CONTRACEPTION UPDATE

July 2007
Volume 2, Issue 7

Summaries of new peer-reviewed publications

Epididymal targets and supporting research
This month’s entire issue of the Asian Journal of Andrology is dedicated to original research on the stucture and function of the epididymis.

“[At] least two different signaling processes are important in regulating the rat epididymis in addition to endocrine regulation: (i) a paracrine signaling process wherein growth factors or other signaling molecules traffic between interstitial and epithelial cells within a given segment, signaling limited to individual segments by the CTS forming the segment borders; and (ii) a lumicrine signaling process wherein intra-luminal molecules can pass from segment to segment, yet are still required for the direct or indirect regulation of thousands of gene expressions in a segment-specific manner.”
Segment boundaries of the adult rat epididymis limit interstitial signaling by potential paracrine factors and segments lose differential gene expression after efferent duct ligation.
Turner TT, Johnston DS, Jelinsky SA, Tomsig JL, Finger JN.
Asian J Androl. 2007 Jul;9(4):565-73.
PMID: 17589796

“As part of our efforts to identify novel contraceptive targets in the epididymis we performed transcriptional profiling on each of the 10 and 19 segments of the mouse and rat epididymidis… Defensin 22 (E3 epididymal protein) was shown to be completely specific for the epididymis.”
Identification of epididymis-specific transcripts in the mouse and rat by transcriptional profiling.
Johnston DS, Turner TT, Finger JN, Owtscharuk TL, Kopf GS, Jelinsky SA.
Asian J Androl. 2007 Jul;9(4):522-7.
PMID: 17589790

“These studies demonstrate that the more abundant D form interacts with spermatozoa transiently, possibly with a specific receptor on the sperm surface, consistent with a capacitation-suppressing function during sperm transit and storage in the epididymis, and also confirm a tightly bound population of the E form that could act in the female reproductive tract.”
Structure and function of epididymal protein cysteine-rich secretory protein-1.
Roberts KP, Johnston DS, Nolan MA, Wooters JL, Waxmonsky NC, Piehl LB, Ensrud-Bowlin KM, Hamilton DW.
Asian J Androl. 2007 Jul;9(4):508-14.
PMID: 17589788

A summary of androgens’ molecular-level actions in the epididymis. We “[determined] the sequence of responses that occur in an androgen deprived tissue upon re-administration of the two metabolites of T, DHT and E2… [and studied] the effects of androgen withdrawal and re-administration on gene expression in immortalized murine caput epididymidal principal cells.”
Androgenic regulation of novel genes in the epididymis.
Robaire B, Seenundun S, Hamzeh M, Lamour SA.
Asian J Androl. 2007 Jul;9(4):545-53.
PMID: 17589794

Discussion of the possible role of the epididymis in the regulatory volume decrease capacity of mature sperm.
Sperm maturation in the epididymis: a new look at an old problem.
Cooper TG.
Asian J Androl. 2007 Jul;9(4):533-9.
PMID: 17589792

“Proteomic analyses indicate that this change [– progressive acquisition of the capacity to phosphorylate tyrosine –] is associated with the phosphorylation of several mitochondrial proteins, creation of a mitochondrial membrane potential and activation of mitochondrial free radical generation.”
Proteomic changes in mammalian spermatozoa during epididymal maturation.
Aitken RJ, Nixon B, Lin M, Koppers AJ, Lee YH, Baker MA.
Asian J Androl. 2007 Jul;9(4):554-64.
PMID: 17589795

Immunological approaches
“[We] localized eppin, lactotransferrin and clusterin in human Sertoli cells and on human testicular and ejaculate spermatozoa, implying that the eppin protein complex (EPC) is present on spermatozoa from the time they leave the seminiferous tubule. On ejaculate spermatozoa eppin, lactotransferrin and clusterin co-localize on the tail. The identification of the EPC components suggests that lactotransferrin, clusterin and/or eppin receptors may function as sperm plasma membrane receptors for the EPC, implicating the complex as a central player in a network of protein-protein interactions on the human sperm surface.”
Characterization of an eppin Protein Complex from Human Semen and Spermatozoa.
Wang Z, Widgren EE, Richardson RT, O'rand MG.
Biol Reprod. 2007 Jun 13; [Epub ahead of print]
PMID: 17567961

“Higher MIF [macrophage Migration Inhibitory Factor] levels determined in men with azoospermia or severe oligozoospermia might be associated with adverse effects of this molecule related to reduced sperm motility… We consistently found that MIF (1 to 20 μg/mL) treatment of healthy spermatozoa dose-dependently decreased sperm total and progressive motility… Low MIF concentrations are indicative of impaired fertilizing ability, which corresponds with the finding that MIF is required for sperm maturation.”
Imbalance in seminal fluid MIF indicates male infertility.
Aljabari B, Calogero AE, Perdichizzi A, Vicari E, Karaki R, Lahloub T, Zatari R, El-Abed K, Nicoletti F, Miller EJ, Pavlov VA, Al-Abed Y.
Mol Med. 2007 Mar-Apr;13(3-4):199-202.
PMID: 17592555

“While there is no doubt that TLRs are important in providing protection against infection in the reproductive tract, there is increasing evidence for the involvement of TLRs in more basic pathology and physiology of reproduction… In the male, toll-like receptors (TLRs) appear to play a role in the control of testicular steroidogenesis and spermatogenesis in disease and, potentially, during normal function, as well.”
Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology.
Girling JE, Hedger MP.
Immunol Cell Biol. 2007 Jun 26; [Epub ahead of print]
PMID: 17592495

Genomic/proteomic supporting research
“[A] number of different classes of receptor have also been detected in these cells and are potential regulators of sperm function. This list includes at least six seven-pass transmembrane receptors, six tyrosine kinase receptors, a tyrosine phosphatase receptor, glutamate-gated ion channel receptors, transient receptor potential cation channels, and a non-genomic progesterone receptor. This is the first published list of identified proteins in human spermatozoa using LC-MS/MS analysis.”
Identification of gene products present in Triton X-100 soluble and insoluble fractions of human spermatozoa lysates using LC-MS/MS analysis.
Baker MA, Reeves G, Hetherington L, Müller J, Baur I, Aitken RJ.
Proteomics Clin. Appl. 2007 1(5):524–532.
DOI 10.1002/prca.200601013

“There are many possible causes of such DNA damage, including abortive apoptosis, the oxidative stress associated with male genital tract infection, exposure to redox cycling chemicals, and defects of spermiogenesis associated with the retention of excess residual cytoplasm. Physical factors such as exposure to radiofrequency electromagnetic radiation or mild scrotal heating can also induce DNA damage in mammalian spermatozoa, although the underlying mechanisms are unclear.”
Origins and consequences of DNA damage in male germ cells.
Aitken RJ, De Iuliis GN.
Reprod Biomed Online. 2007 Jun;14(6):727-33.
PMID: 17579989

“[INSL3] Receptor expression was markedly increased after birth and readily detectable in the epididymis, Leydig and germ cells of the testis. The strongest expression was detected in adult mouse cremaster muscle. INSL3 treatment increased cell proliferation of embryonic gubernacular and TM3 embryonic Leydig cells implicating active INSL3-mediated autocrine signaling in these cells and identifying TM3 as a novel in vitro model to study the effects of RXFP2 signaling.”
Developmental Expression and Gene Regulation of Insulin-like 3 Receptor RXFP2 in Mouse Male Reproductive Organs.
Feng S, Bogatcheva NV, Truong A, Korchin B, Bishop CE, Klonisch T, Agoulnik IU, Agoulnik AI.
Biol Reprod. 2007 Jul 5; [Epub ahead of print]
PMID: 17615407

“The common INSL3 G178A polymorphism was not statistically significantly associated with male infertility (P>.05), even though INSL3 is essential for the occurrence of bilateral cryptorchidism.”
Preliminary analysis of the G178A polymorphism of insulin-like factor 3 in male infertility.
Yun YJ, Lee HC, Kim JE, Song SH, Lee S.
Fertil Steril. 2007 Jun 6; [Epub ahead of print]
PMID: 17559848

In an examination of the sperm of 13 infertile men presenting for ICSI, the researchers found no evidence of inner acrosome IZUMO absence. They speculate that “men with dysfunction of IZUMO would only be able to leave a descendant by the use of ICSI, which has been performed in infertility treatments for only the past 15 years. Prior to 15 years ago, they would have been lost from the population because of their infertile phenotype. As this would make such individuals quite rare, our sample size was likely insufficient to identify them.”
Positive expression of the immunoglobulin superfamily protein IZUMO on human sperm of severely infertile male patients.
Hayasaka S, Terada Y, Inoue N, Okabe M, Yaegashi N, Okamura K.
Fertil Steril. 2007 Jul;88(1):214-6. Epub 2007 Feb 12.
PMID: 17296188

“[We] describe a procedure to cryopreserve the postnatal members of the Leydig cell lineage, including progenitor (PLC), immature (ILC) and adult (ALC) Leydig cells from, respectively 21-, 35- and 90-day-old rats… This study demonstrates that purified rat Leydig cells at a range of developmental stages can be frozen and that the cryopreserved cells retain normal function.”
Development of a cryopreservation protocol for Leydig cells.
Chen GR, Ge RS, Lin H, Dong L, Sottas CM, Hardy MP.
Hum Reprod. 2007 Jun 27; [Epub ahead of print]
PMID: 17596277

Fusion targets
“That anti-DE and anti-Tpx-1 inhibit sperm-egg fusion while recognizing only the corresponding proteins, suggests functional cooperation between these homologous CRISP to ensure fertilization success. These results increase our understanding of the molecular mechanisms of gamete fusion and contribute to the development of new and safer fertility regulating methods.”
Participation of epididymal cysteine-rich secretory proteins in sperm-egg fusion and their potential use for male fertility regulation.
Cohen DJ, Da Ros VG, Busso D, Ellerman DA, Maldera JA, Goldweic N, Cuasnicu PS.
Asian J Androl. 2007 Jul;9(4):528-32.
PMID: 17589791

Capacitation & binding targets
“By imaging the calcium responses generated in individual [sperm] cells, we have demonstrated that… spermatozoa exhibit a series of asynchronous secondary calcium oscillations… The oscillations were dependent upon the influx of extracellular calcium via mechanisms that were insensitive to inhibitors of L-type voltage operated calcium channels (nifedipine, verapamil, diltiazem), G-proteins (pertussis toxin) or the GABA (A) receptor (bicuculline). However, treatment with an inhibitor of the GABA-associated chloride channel (picrotoxin) significantly suppressed the incidence of secondary calcium oscillations in pentoxifylline-treated cells, as did two inhibitors of T-type calcium channels (pimozide and amiloride).”
Molecular mechanisms of sperm capacitation: progesterone-induced secondary calcium oscillations the attainment of a capacitated state.
Aitken RJ, McLaughlin EA.
Soc Reprod Fertil Suppl. 2007;63:273-93.
PMID: 17566279

“[Capacitation] is associated with an increase in both [human] sperm-zona binding and an increase in tyrosine phosphorylation over the sperm tail. However, we could not detect the surface expression of phosphotyrosine residues over the sperm head, as observed with murine spermatozoa… [Strong] species-specific differences exist in the molecular mechanisms that drive sperm-egg recognition and that alternative, chaperone-independent, mechanisms must underpin sperm-zona interaction in the human.”
Analysis of chaperone proteins associated with human spermatozoa during capacitation.
Mitchell LA, Nixon B, Aitken RJ.
Mol Hum Reprod. 2007 Jun 26; [Epub ahead of print]
PMID: 17595329

“Interestingly, addition of a CFTR [cystic fibrosis transmembrane conductance regulator] inhibitor (DPC 250 microM) inhibited the capacitation-associated hyperpolarization, prevented ENaC [epithelial sodium channel] closure and decreased the zona pellucida-induced acrosome reaction without affecting the increase in tyrosine phosphorylation… These results suggest that cAMP-dependent Cl- fluxes through CFTR are involved in the regulation of ENaC during capacitation and thus contribute to the observed hyperpolarization associated to this process.”
Involvement of cystic fibrosis transmembrane conductance regulator in mouse sperm capacitation.
Hernández-González EO, Treviño CL, Castellano LE, de la Vega-Beltran JL, Ocampo AY, Wertheimer E, Visconti PE, Darszon A.
J Biol Chem. 2007 Jun 22; [Epub ahead of print]
PMID: 17588945

Heat-based approach supporting research
“The mRNA of the mitochondrial uncoupling protein 2 (UCP2) was up-regulated by cryptorchidism, a testicular hyperthermic condition under which germ cells undergo severe apoptosis. We investigated whether UCP2 was able to protect germ cells from hyperthermia-induced apoptosis.” UCP2 had a protective effect after 5 minutes of 43˚C treatment, but not after 15 minutes.
Uncoupling protein 2 protects testicular germ cells from hyperthermia-induced apoptosis.
Zhang K, Shang Y, Liao S, Zhang W, Nian H, Liu Y, Chen Q, Han C.
Biochem Biophys Res Commun. 2007 Jun 21; [Epub ahead of print]
PMID: 17603020

Review
Current status and future perspectives in male contraception.
Costantino A, Cerpolini S, Perrone AM, Ghi T, Pelusi C, Pelusi G, Meriggiola MC.
Minerva Ginecol. 2007 Jun;59(3):299-310.
PMID: 17576406

Return to the top

“The Future of Male Contraception” conference coming up!

The second future of Male Contraception conference – sponsored by the National Institute of Child Health and Human Development, CONRAD, the World Health Organization, and the University of Washington – is fast approaching. The conference will be on September 27 and 28, 2007, at Seattle ’s Edgewater Hotel overlooking the Puget Sound.

The deadline to submit abstracts is August 15th. Rooms at group rates are being held until August 24th. To register, submit an abstract, or find further information, see the conference website: http://www.futureofmalecontraception.com

Preliminary program

Thursday - September 27
8:15 - 8:30 AM Welcome and Goals of the Meeting - Diana Blithe
8:30 - 10:00 AM Session 1 CLINICAL UPDATES
    Recovery after Male Hormonal Contraception - Peter Liu
    DMPA + T Gel /Acyline - Stephanie Page
    Nonsteroidal SARM Ligands- James Dalton
    Progestin Effects on Gonadotropin Levels - Eberhard Nieschlag
    Normal and Subnormal Semen Parameters - Eberhard Nieschlag

10:00 - 10:30 AM Coffee Break
10:30 AM - 12:30 PM Session 2 PROMISING TARGETS
    K+ Channel Blockers and Sperm volume regulation: a contraceptive opportunity? Trevor Cooper
    Soluble Adenylyl Cyclases - Marco Conti
    Na+H+ Exchanger regulation of sperm motility - Dan Wang
    PKA as a Target for Male Contraception- Daniel Morgan
    Eppin: Development as a Male Contraceptive Target - Michael O’Rand

12:30 - 1:30 PM LUNCH
1:30 - 3:30 PM Session 3 PROMISING NEW AGENTS
    Orally Active Androgens - Barbara Attardi
    Retinoic Acid Alpha Receptor Inhibitor as a Contraceptive - Debra Wolgemuth
    CDB-4022: a Potential Oral Nonsteroidal Male Contraceptive - Sheri Hild
    A model for the anti-spermatogenic action of Gamendazole - Joseph Tash

3:30 -4:00 PM Coffee Break
4:00 - 5:30 PM Session 4 TECHNOLOGY
    Challenges of the Blood Testes Barrier - Robert Braun
    Drug Targeting to the Testis- C. Yan Cheng
    High-throughput Screening & Drug Design - Gunda Georg

7:00 - 9:00 PM POSTER SESSION

Friday, September 28
8:30 - 10:30 AM Session 5 PROMISING TARGETS
    Novel Sperm Glycolytic Enzymes as Contraceptive Targets - Deborah O’Brien
    Catecholamine inhibitors - Donner Babcock
    ZPBPs in Sperm-Egg Interactions and Acrosome Formation - Martin Matzuk
    Na,K-ATPase - A sperm-specific isoform as a target for male contraception - Gustavo Blanco
    CatSper; The Sperm-Specific Calcium Channel as a Target for Male Contraception- David Clapham

10:30 - 11:00 AM Coffee Break
11:00 AM - 12:30 PM Session 6 CLINICAL UPDATES
    Oral Testosterone Enanthate plus Dutasteride- John Amory
    Oral Acyline - William Bremner
    Nestorone and Testosterone Gels - Christina Wang
    Intra Vas Device - Janelle Antil

12:30 - 1:30 PM Lunch
1:30 - 3:30 PM Session 7 GENERAL UPDATES
    Testicular Gene Expression after Hormones and Heat - Ronald Swerdloff
    Acceptability of Male Contraceptives - Albert Radlmaier
    Bayer Schering Pharma Update - Ulrich Gottwald

3:30 - 4:00 PM Coffee Break
4:00 - 5:00 PM Resources for Translational Research/Product Development
    NIH- RAID program
    Intellectual Property considerations at Universities

Return to the top

New hope for research funding at USAID

Over the past few weeks members of the House and Senate Appropriations committees have decided how much money to give to the U.S. Agency for International Development (USAID), which is a crucial funder of contraceptive research. Scores of you took the time to let your congressmembers know how important this is to you, and it appears that Congress has listened.

The Senate Appropriations Committee budgeted $461 million for family planning and reproductive health programs, which is $137 million above the President’s request and about $20 million above the 2007 level. This is a good sign that Congress considers USAID’s work important. It allows room for research to be maintained, rather than be cut severely like in recent years, if some of the money is set aside for research rather than sent out to field offices.

The House budget language doesn't increase USAID funding, but at least it's a welcome change from years of cuts.  And the house committee includes language specifically supporting USAID's R&D work: "The Committee believes that USAID’s support for research and development on diseases and conditions that impact the developing world is important. These investments will leverage additional resources from foundations, private corporations and other country governments, including European donors."

Now that the subcommittees have written in the funding and the Appropriations Committees have approved it, we will monitor the bill’s progress as it moves forward in the Senate, the conference committee, and the signing process.

We hear that there may be Congressional action soon to defend research funding at USAID, and USAID has also let the affected organizations know that it is listening carefully to them on this issue.

Read more:
• Senate Appropriations Committee Approves FY 08 State/Foreign Operations Bill
  Global Health Council
• On World Health Care, Spend Smarter
  By Laurie Garrett, as an op/ed in the Washington Post

Return to the top

Standardization of terms: oligo- and azoospermia

Drs. David Grimes and Laureen Lopez argue for the abandonment of the terms “oligospermia”, “azoospermia” and the like, on multiple grounds. The definitions of the words are variable and overlapping, confusing patients and medical caregivers alike. Furthermore, the terms have little predictive value.

“Because WHO has now abandoned quantitative definitions, these terms should be discarded as well. Instead, physicians and scientists should report semen analysis numerically. Moreover, using arbitrary dichotomous labels for continuous variables (e.g., sperm count) loses information: continuous data should be presented as such, and not be dichotomized above or below some cut point… Adoption of better, more scientific terminology will improve both research and clinical practice in andrology. The current nomenclature is simply untenable.”

Read more:
"Oligozoospermia," "azoospermia," and other semen-analysis terminology: the need for better science.
Grimes DA, Lopez LM.
Fertil Steril. 2007 Jun 18; [Epub ahead of print]
PMID: 17582404

Return to the top

Press highlights

More about Bayer’s decision to quit research on hormonal male contraception; includes quotes from MCIP’s director.
Big pharma not interested in 'male pill'
Chemistry World, 22 June

Hormonal male contraception development at Edinburgh University in Scotland has been hit by the lack of funding from drug companies; Prof. Richard Anderson discusses possible reasons.
Hopes for Male Pill hit by lack of cash
Scotsman, 2 July

Researchers found that a high semen level of macrophage migration inhibitory factor, or MIF for short, was a good predictor of a man’s reduced fertility. The researchers make the news wondering whether administering MIF might work as a form of male contraception.
Key to male infertility
Science Daily, 2 July

“With male birth control's possible ability to ease these problems, it's time for women, and especially men, to change the way they look at contraceptives. And if women and men are to continue to share responsibilities in the workplace and at home, they must also share the responsibility of birth control.”
Viewpoint: Why we need male birth control
The Daily Texan, 20 June

A GnRH agonist approved for use in male dogs in Australia and New Zealand gets new European approval.
Reversible contraceptive to spare dogs the snip
The Telegraph, 12 July

Return to the top

Calendar of events

Planning to attend a male contraception or andrology-related event that's not listed here? Let us know so we can post it and alert your colleagues to interesting upcoming events.

July 1-4
23rd Annual Meeting of the European Society of Human Reproduction and Embryology; Lyon, France
July 1-6
Gordon Research Conferences Cell-Cell Fusion; New London, NH, USA
July 2
Deadline for the World Congress on Men's Health abstract submission
July 15-20
Gordon Research Conferences Fertilization and Activation of Development; Plymouth, NH, USA
July 21-25
40th Annual Meeting of the Society for the Study of Reproduction; San Antonio, TX, USA
August 4-9
FASEB Summer Research Conference on the Biology of Cilia and Flagella; Saxtons River, VT, USA
August 15
Deadline for Future of Male Contraception conference abstract submission
September 14-16
Florence-Utah International Symposium: Genetics of Male Infertility; Florence, Italy
September 21-23
5th Biennial World Congress on Men's Health and Gender; Vienna, Austria
September 26-29
53rd Annual Meeting of the Canadian Fertility and Andrology Society; Halifax, Nova Scotia, Canada
September 27-28
2nd Future of Male Contraception conference; Seattle, WA, USA
September 30
Deadline for British Andrology Society abstract submission
October 13-17
63rd Annual Meeting of the American Society for Reproductive Medicine; Washington, DC, USA
November 1
Deadline for American Society of Andrology abstract submission
November 3-7
American Public Health Association 2007 Annual Meeting “Politics, Policy & Public Health”; Washington, DC, USA
November 15-16
British Andrology Society Annual Meeting; Ware, Hertfordshire, UK
November 16-18
2nd Japan - ASEAN Men's Health & Aging Conference; Ishikawa, Japan
2008
January 1
Deadline for European Society of Contraception abstract submission
April 12-15
33rd Annual Conference of the American Society of Andrology; Albuquerque, NM, USA
April 30 - May 3
10th Congress of the European Society of Contraception; Prague, Czech Republic
May 3-7
10th European Congress of Endocrinology; Berlin, Germany

 

Return to the top

Editors

Kirsten Thompson, Director of the Male Contraception Coalition (MCC)
Email: Kirsten@MaleContraceptives.org
Phone: +1 (443) 858-1183

Elaine Lissner, Director of the Male Contraception Information Project (MCIP)
Email: Lissner@NewMaleContraception.org
Phone: +1 (415) 863-1859 x107